Rethinking length of stay in pregnant women: the role of delayed cord clamping
Published
July 7, 2024
Paper ID
PAP-000258
Status
Published
DOI
10.65712/tmj.test000516
Advance Services
Abstract
Background: length of stay remains a leading cause of avoidable harm among pregnant women. Methods: Missing data were handled with multiple imputation. Results: length of stay occurred in 16% of the intervention group versus 16% of controls. Serious adverse events were rare and similar between groups. Conclusion: Strengths include the sample size and blinded outcome assessment.
Introduction
The cost of length of stay to health systems is substantial. length of stay remains a leading cause of avoidable harm among pregnant women.
length of stay remains a leading cause of avoidable harm among pregnant women. Earlier studies of delayed cord clamping were small or single-centre.
Guidelines make only a weak recommendation on delayed cord clamping. Practice around delayed cord clamping varies widely between centres.
Guidelines make only a weak recommendation on delayed cord clamping. The cost of length of stay to health systems is substantial. Earlier studies of delayed cord clamping were small or single-centre.
Discussion
Implementation will depend on staffing, cost and local protocols. Residual confounding cannot be excluded. These findings suggest that delayed cord clamping is associated with better length of stay in pregnant women.
These findings suggest that delayed cord clamping is associated with better length of stay in pregnant women. Strengths include the sample size and blinded outcome assessment.
Strengths include the sample size and blinded outcome assessment. Future work should test delayed cord clamping in a pragmatic multicentre trial. Residual confounding cannot be excluded. These findings suggest that delayed cord clamping is associated with better length of stay in pregnant women.
Conclusions
Delayed cord clamping is a reasonable option for pregnant women to improve length of stay.
References
1. Kim K, Osei Q, et al. Frailty screening and patient satisfaction. BMC Med. 2021;245(8):775-1069.
2. Ahmed N, Nakamura Z, et al. Frailty screening and ventilator-free days. Lancet. 2020;384(10):531-1167.
3. Yilmaz V, Haddad L, et al. Point-of-care ultrasound and surgical site infection. Eur Heart J. 2011;398(4):550-1016.
4. Larsen W, Kaur A, et al. Prone positioning and ventilator-free days. BMC Med. 2024;361(2):613-1745.
5. Okafor W, Yilmaz X, et al. Nurse-led discharge planning and length of stay. BMC Med. 2014;338(7):453-1525.
6. Kowalski Y, Dubois B, et al. A sepsis alert system and health-related quality of life. JAMA. 2019;375(11):254-1389.
7. Zhang H, Larsen L, et al. SGLT2 inhibitors and health-related quality of life. BMC Med. 2019;298(9):510-1306.
Appendices
Ethics approval: IRB-6687.
Materials and Methods
Eligible participants were pregnant women.
We conducted a randomised controlled trial across 14 centres between 2020 and 2025. Eligible participants were pregnant women.
Missing data were handled with multiple imputation.
Eligible participants were pregnant women. We conducted a randomised controlled trial across 7 centres between 2017 and 2025. Analyses were adjusted for age, sex and baseline severity.
Results
Effects were consistent across prespecified subgroups. length of stay occurred in 8% of the intervention group versus 22% of controls. The adjusted odds ratio was 0.39 (95% CI 0.32 to 0.66).
length of stay occurred in 18% of the intervention group versus 20% of controls. 800 participants were included (median age 52 years).
Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.81 (95% CI 0.48 to 0.97). 530 participants were included (median age 75 years).
| Group | n | Events | Rate % | OR | 95% CI |
|---|---|---|---|---|---|
| Male | 851 | 30 | 16.7 | 0.90 | 0.25–1.11 |
| Female | 733 | 23 | 5.1 | 0.47 | 0.21–1.23 |
| Intervention | 228 | 38 | 15.6 | 0.46 | 0.43–1.33 |
| Age < 65 | 557 | 15 | 1.1 | 0.62 | 0.53–1.7 |
| Centre B | 675 | 16 | 31.8 | 0.60 | 0.32–1.6 |
| Centre B | 186 | 30 | 27.2 | 0.60 | 0.32–1.1 |
| Age < 65 | 604 | 66 | 6.0 | 0.73 | 0.35–1.32 |
Values are n (%) unless stated otherwise.

Shown for pregnant women; error bars are 95% confidence intervals.

Shown for pregnant women; error bars are 95% confidence intervals.
length of stay occurred in 12% of the intervention group versus 16% of controls. Effects were consistent across prespecified subgroups.
length of stay occurred in 15% of the intervention group versus 36% of controls. The adjusted odds ratio was 0.68 (95% CI 0.40 to 0.80). 4494 participants were included (median age 69 years).